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PATHOGENESIS
Coreceptor Usage, Diversity, and Divergence
in Drug-Naive and Drug-Exposed Individuals from Malawi,
Infected with HIV-1 Subtype C for More Than 20 Years
Ishla Seager,1 Simon A. Travers,1,2 Michael D. Leeson,1 Amelia C. Crampin,3,4 Neil French,3–5
Judith R. Glynn,4 and Grace P. McCormack1
Abstract
There are few cohorts of individuals who have survived infection with HIV-1 for more than 20 years, reported and
followed in the literature, andeven fewer fromAfrica.Herewepresent dataonacohort of subtypeC-infected individuals
from rural northernMalawi. By sequencingmultiple clones from long-term survivors at different time points, and using
multiplegenotypingapproaches,we showthat 5of the11 individuals arepredictedasCXCR4using (by‡3/5predictors)
but only one individual is predicted as CXCR4 using by all five algorithms. Using any one genotyping approach
overestimates the number of predicted CXCR4 sequences. Patterns of diversity and divergence were variable between
the HIV-1 long-term survivors with some individuals showing very small amounts of variation and change, and others
showing a greater amount; both patterns are consistent with what has been described in the literature.
Introduction
HIV/AIDS continues to be one of the most significantinfectious diseases globally. The median time to death
without treatment is 10 years, but progression is highly variable,
being faster in older individuals.1,2 Some patients can remain
asymptomatic for over 15 years while maintaining a healthy
immunesystemand remaining therapynaive.Those thatmaintain
a highCD4+ Tcell count are knownas long-termnonprogressors
(LTNPs)while those that showadecline inCD4+ Tcell numbers
over an extendedperiod of time are knownas long-term survivors
(LTS) or slow progressors3 and very little is known about what
allows for natural control of theHIV-1 virus in these individuals.4
Someevidence suggests thatmostLTNPsare infectedwitha fully
pathogenic replication-competent virus5,6 but several other stud-
ies have linked viral attenuation to mutations in particular viral
genes such as env, gag, nef, vpu, vif, rev, and tat.7–13
Peoplewho survive for an extended periodwhile infectedwith
HIV-1 serve as important models for effective immunologic
control of this virus, and can provide clues to natural therapeutics
and therapeutic vaccines. There are few cohorts of survivors who
have been followed for 20 years and those that have survived are
found in Europe, America, and Australia, with the majority fo-
cused on individuals infected with subtype B.14–18 Very little
information is available in the literature on nonprogression in
Africa and even less information on subtype C [e.g., Tzitzivacos
et al.19 in children and Archary et al.20 (in adults)] with the
average follow-up being less than 2 years. Laeyendecker et al.21
and Fang et al.22 studied long-term survivors in Uganda and
Nairobi, respectively;however, neither of these studieswasbased
on individuals infected with subtype C. An LTS cohort in Kar-
onga District Malawi provides a unique opportunity to inves-
tigate viral patterns in a group of primarily subtype C LTS in
sub-Saharan Africa who have been followed for over 20
years.23–25 The extensive period of follow-up on the LTS in
Karonga has allowed us to examine changes in the subtype C
viral populationwithin some individuals over a 20-year period.
In the majority of HIV-1 infections with subtype B, CCR5
tropic viruses are found to predominate during early infec-
tion.26–28 In approximately 50% of subtype B infections,
CXCR4 usage subsequently emerges and is often associated
with accelerated loss inCD4+ Tcells andprogression to clinical
AIDS.27, 29–31 Studies on subtype C have reported that viral
isolates almost exclusively use the CCR5 coreceptor with
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CXCR4 usage being observed only very rarely even within in-
dividualswithmoreadvanceddiseaseprogressionandwhohave
advanced to AIDS. Despite the fact that subtype C represents
over 50% of HIV-1 infections worldwide, relatively few
CXCR4-utilizing subtype C viruses had been isolated up to
2008.32–39More recently, two studies found that approximately
30% of subtype C viral isolates retrieved from individuals with
advanced disease could efficiently utilize CXCR4 in vitro.40,41
Here, we used a genotyping approach to investigate coreceptor
usage among the LTS inKaronga overmultiple time periods, to
identify any switch in coreceptor usage as some individuals
began to exhibit signs of progression.
Materials and Methods
Patients and samples
LTS were visited four times between the 1980s and 2010.
Of nearly 200 individuals identified as HIV positive during
population surveys in Karonga District Malawi in the 1980s,
38 were alive and agreed to give a blood sample in the 1990s.
In 2004, 17 were reported to be still alive but not all indi-
viduals were seen or consented to the study and therefore
dried blood spot samples were collected only from 10. In
2010 13 individuals were sought: two had died, one had left,
and one refused to participate, so nine whole blood samples
Table 1. Summary of Sequence Data, Coreceptor Tropism, CD4 + Counts,
and Antiretroviral Therapy Status for Each Long-Term Survivor
LTS
number Year
Consensus
sequences R5/X4 Number of clones
Cloned
sequences R5/X4
CD4 T cell count
and ART status
LTS1 1999 R5 2004–586
2010 R5 18 env, 17 gag R5 2010–449
No ART
LTS2 1999 R5
2008 NA 20 env X4 ART–2009
2010 R5 22 env, 20 gag 2R5, 20X4 2010–244
LTS5 1998 R5 and X4? ART–2008
2010 NA 22 env, 19 gag R5 2010–789
LTS8 1989 R5
1999 R5
2004 R5 20 env, 30 gag R5 2004–265
2008 NA 39 env R5 2005–ART
2010 R5 23 env, 19 gag R5 2010–734
LTS9 1988 R5
1999 R5
2004 R5 20 env, 20 gag R5 2004–56
Died 2008
LTS10 1989 R5
1999 R5
2004 R5 20 env, 20 gag R5 2004–328
2010 X4? 23 env, 20 gag R5 2010–138
LTS12 1988 R5
1999 R5 2004–390
2004 R5 20 env, 20 gag R5 2006–ART
2010 R5 20 env, 19 gag R5 2010–439
LTS17 1989 R5
1998 R5
2004 X4? 20 env, 20 gag X4? 2004–452
LTS20 1988 R5
2000 R5
2004 R5 ART–2006
2010 R5 18 env, 19 gag R5 2010–139
LTS21 1989 R5
1999 R5 2004–47
2010 R5 21 env, 18 gag R5 2010–36
LTS22 1989 R5
1998 R5
2004 R5 19 env, 20 gag 18R5, 1X4? 2003–475
2005–Died
LTS30 2010 R5 19 env R5 2004–675
2010–362
A different combination of three genotypic prediction tools predicted the X4?; only for LTS 2 were all five tools concordant.
LTS, long-term survivor; ART, antiretroviral therapy.
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were collected (Table 1). Two individuals (LTS2 and LTS8)
were seen in unrelated studies in 2008 and whole blood cell
pellets were available from that time also. LTS21 and LTS1
were suspected to be dual infected.23 By 2010 five LTS had
been placed on antiretroviral therapy (ART) (LTS2, 5, 8, 12,
and 20) and two other individuals, LTS10 and LTS21 had
been referred for ART due to low CD4 + counts of 138 and 36
cells/mm3, respectively. Two LTS had CD4 + counts greater
than 200 cells/mm3 (LTS1 subtype C and LTS30 unclassifi-
able) and have not been referred for ART (following national
guidelines) (Table 1).
DNA extraction, PCR, and sequencing
Proviral DNA was extracted from the dried blood spot
(DBS) using a QIAamp DNA Micro Kit (Qiagen) or from
200 ll of cell pellets using a QIAamp DNA Blood Mini Kit
(Qiagen). Nested polymerase chain reaction (PCR) of a 750-
bp region of gag p17p24 and a 549-bp region of env C2V3
was carried out as previously described.42 A consensus se-
quence was produced from gel-purified PCR products where
possible and for some samples more than one consensus se-
quence was produced. Three secondary PCR products were
pooled and TA cloned using the pCR2.1-TOPO Cloning Kit
(Invitrogen) or using the StrataClone PCR Cloning Kit
(Agilent Technologies). Approximately 20 individual clones
were sequenced in one direction. Sequence chromatographs
were examined for quality in Seqman 8.0.2 (DNASTAR). All
clonal data were aligned to consensus sequences already
available from the 1980s, 1990s, 2004, and 201023,42 in
MacClade 4.0 (Sinauer Associates) and additional sequences
randomly chosen from the overall Karonga dataset (20 se-
quences retrieved in 1990s and 20 retrieved in 2008).
Sequence analysis
Phylogenetic trees were reconstructed under the GTR +
gamma model of DNA substitution implemented by RAxML
7.0.343 with all parameters optimized by RAxML. Con-
fidence levels in the groupings in the phylogeny were as-
sessed using 1,000 bootstrap replicates as part of the RAxML
phylogeny reconstruction. The subtype C ancestral sequences
derived by Travers et al.44 were employed as out-groups for
env and gag gene trees. In addition, multiple alignments of
each gene region were assembled for each LTS individually
and phylogenetic trees were reconstructed in a manner sim-
ilar to that described above. Pairwise evolutionary genetic
distances from nucleotide sequences were computed by
PAUP* 4.0 (D.L. Swofford, Sinauer Associates, Inc.) under
Kimura’s two-parameter model of evolution.45 Intrapatient
genetic divergence was examined by estimating the genetic
distance from the earliest sequence available and all subse-
quent time points. Intrapatient genetic diversity at each
available time point was also estimated. Coreceptor usage
was determined for all env sequences for all of the LTS using
five genotypic predictor tools: C-PSSM, Geno2pheno (5%
FPR), CoRSeqV3-C, GPGQ, and Raymond.41,46–50
Results
Prediction of coreceptor tropism
LTS30, an unclassifiable subtype, was predicted as being
R5 tropic. For subtype C sequences there was little congru-
ence (15%) between all five genotypic prediction approaches.
CoRSeqV3-C was found to overpredict CXCR4 usage sug-
gesting that 94% of the subtype C sequences here were X4
tropic. When this predictor was excluded, 286 R5 and 41X4
tropic sequences are predicted as such by all four remaining
methods, a concordance of 80%. CPSSM also predicted a
higher number of X4 tropic sequences compared to Geno2-
pheno, GPGQ, or Raymond methods. All env sequences from
five of the subtype C LTS (LTS1, 8, 9, 12, and 20) were
predicted to be R5 tropic at all time points for which sequence
information was available (Table 1 and Supplementary
Table S1; Supplementary Data are available online at www
.liebertpub.com/aid). Four individuals (LTS2, 10, 17, and 22)
were indicated as having X4 tropic viruses at some point
during the course of their infection by three of more of the
predictors. Only one LTS (LTS2) showed CXCR4 usage by
all five predictors. X4 tropic viruses constituted > 90% of the
sequenced viral population within two individuals (LTS2 and
17) at the time of the last sampling time point (Fig. 1).
The consensus sequences for LTS2 from 2010 and two of
the cloned sequences from the same time point were pre-
dicted to use CCR5. The remaining clones from this time
point were predicted to use CXCR4. The phylogenetic re-
construction (Fig. 1a) of the env C2-V3 fragment from LTS2
showed two viral lineages; one contained all CXCR4 tropic
viruses from 2008 with the R5 consensus from 1999 as a
distant sister, and the other showed a clade of CXCR4 se-
quences from 2010 having emerged from a CCR5 ancestral
strain. LTS2 had been on ART since 2009.
One of the envV3 consensus sequences retrieved from 1999
from LTS10 was predicted to be CXCR4 tropic by CPSSM-C
andCoRSeqV3-C approaches as were all sequences from 2004
with the exception of one clone retrieved from the 2004 sam-
ple. This single 2004 CCR5 sequence shared a most recent
common ancestor with clones from 2010 predicted as X4 by
CPSSM only. The consensus sequence from 2010 was pre-
dicted as X4 also by geno2pheno and is the only sequence color
coded as X4 tropic on Fig. 1b. LTS10 had a CD4+ count of 138
cells/mm3 in 2010 and was subsequently referred for ART.
V3 sequences obtained from LTS17 in 1998 were pre-
dicted to be CCR5 tropic (Fig. 1c) but by 2004 both the
consensus sequence and 20 cloned sequences were predicted
to use CXCR4 by CPSSM, CoRSeqV3-C, and the Raymond
method. No further follow-up information was available for
LTS17, as the individual had left the Karonga region by 2010.
For LTS5 two consensus sequences were available from
1998. Of these one sequence was predicted to use CCR5
while another was predicted to use CXCR4 (by CPSSM-C,
CoRSeqV3-C, and GPGQ). Cloned sequences dating from
2010 were CCR5 tropic. V3 sequence data were available
from LTS22 from 1989, 1998, and 2004 (Fig. 1e); all were
predicted to utilize CCR5 except one of 19 clones from 2004
(X4 by Geno2Pheno, Raymond, and CPSSM-C approaches).
The patient died of AIDS in 2005.
Genetic diversity and divergence
Clonal sequences from within a time point from four of the
nine LTS (LTS2, 5, 9, and 20) were homogenous (i.e., very
similar if not identical) in both genes, and the consensus
sequence from each time period grouped with the clones
from that time period. The average gag pairwise genetic
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distances between all the clones from one time point within
these individuals varied from 0% in LTS5 to 0.4% in LTS9
and 0.1–0.2% between all the clonal sequences from one time
point in env (Tables 2 and 3). In other LTS (LTS17, 12, and
22) genetic diversity was more variable but sequences within
a time period still grouped together. For LTS17 the genetic
distance between gag clones was 1.6% while the env clones
were homogeneous, while in LTS12 gag clones in each time
period, and the env clones in 2010, were homogeneous but
there was a good deal of diversity in the env clones in 2004.
LTS22 contained a number of variant clones in 2004 for both
genes with an average pairwise genetic distance of 1.6% in
gag and 2% in env (Fig. 1, Fig. 2, Tables 2 and 3).
Within LTS8, by comparison, gag and env clones did not
always group with the consensus sequence of the same time
period (e.g., Fig. 2d). Within LTS10 the gag clones from
2010 exhibited a high level of genetic diversity and the 1999,
2004, and 2010 consensus sequences (Fig. 2e) all grouped
within the same clade as these clones. The clones from 2004
formed a separate but homogeneous sister clade to this with
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*
*
*
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FIG. 1. Individual maximum likelihood trees generated from all env sequences for individual long-term survivors (LTS);
(a) LTS2, (b) LTS10, (c) LTS17, (d) LTS5, (e) LTS22, (f) LTS21. x represents clones dating from 2004, , represents
clones dating from the 2008, and - represents clones dating from 2010. Green = sequences predicted to use CCR5 and
red = sequences predicted to use CXCR4. Bootstrap values of over 70 are marked with an asterisk (*) on the relevant
branches.
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both lineages supported by high bootstrap values. However,
the env 2004 and 2010 cloned sequences from LTS10 (Fig.
1b) showed very little variation within each time point with
the exception of one clone from 2004 that grouped within the
clones from 2010. A large amount of change had occurred
between 2004 and 2010 resulting in a long branch separating
the two clades with an average pairwise genetic distance of
12.2% between the two sets of clones. Seven of the nine
individuals included showed an overall increase in pairwise
genetic divergence between the first sampling time point in
1988/89 and the last sampling time point of either 2004
(LTS9, 17, and 22) or 2010 (LTS5, 8, 9, and 10) (Tables 2 and
3). However, in LTS12 a decrease in divergence was seen
between the first sequence information from 1999 and the last
sampling time point in 2010 in both genes (Tables 2 and 3).
Discussion
Early studies of subtype C tropism reported little if any
usage of the CXCR4 coreceptor.32,34,39,51 More recently,
Connell et al.40 found that 30% of isolates from 20 subtype
C-infected individuals with AIDS from South Africa were
able to use CXCR4 for cell entry. Raymond et al.41detected
CXCR4 tropic virus in 29% of 52 subtype C-infected indi-
viduals who had started ART in Malawi, while Jakobsen
et al.52 describe CXCR4 tropic virus detected in one of 21
ART-naive individuals in Zimbabwe who had progressed to
advanced stages of HIV-1subtype C infection. In this study
while CXCR4 tropic viruses were predicted in 5 out of 11
individuals by multiple genotypic prediction tools, in only
one individual was X4 usage predicted by all five approaches.
Studies on subtype C samples where both phenotypic
methods and C-PSSM were used showed good concordance
between the results (C-PSSM displayed a specificity of
over 93% in detecting CXCR4 tropism).40,41,47 In addition,
the European Consensus Group on clinical management of
HIV-1 tropism testing has recently indicated that genotyping
approaches can be sufficient for determining resistance to
CCR5 antagonists.53 Due to a lack of appropriate samples at
each time point phenotypic approaches could not be pursued
for these individuals. This work clearly shows, however, that
additional work needs to be done to elucidate the relationship
between these two approaches for successful development of
a genotypic predictor tool.
LTS10 was referred for ART in 2010 as the CD4 + cell
count had dropped to 138 cells/mm3 indicating progression,
which was 6 years after viruses able to use CXCR4 are pre-
dicted (but only by two genotypic predictor tools). This may
suggest that a switch to CXCR4 tropism within subtype C is
not as strongly correlated with disease progression, consistent
with the suggestion byMeehan et al.54 that CXCR4 usage can
be transitory during disease progression. It may be that ge-
notypic prediction by some but not all predictor tools indi-
cates an intermediate phase or a dual phase for coreceptor
usage or indeed that genotypic predictor tools are not yet
sensitive enough to accurately predict coreceptor usage in
subtype C. Of the six LTS who have been placed on ART,
suggesting disease progression, four were CCR5 tropic, and
of the two who had died one (LTS9) was at no time predicted
to utilize CXCR4. However, as all of these individuals were
classified as LTS, further exploration of the emergence
of CXCR4 usage in nonprogressors as well as normal
Table 2. Average Pairwise Genetic Diversity
in gag and Average Pairwise Divergence
(Between the Sequence from the Earliest Time
Point and All Sequences Available from
Each Subsequent Time Point) from
Long-Term Survivor Where Data Were Available
LTS
Genetic
diversity in gag
Genetic
divergence in gag
number 2004 2010 1990s 2004 2010
LTS2 0.2% 2.1%
LTS5 0.0% 1.5% 1.2% 3.3%
LTS8 0.3% 1.2% 1.5% 2.2% 2.5%
LTS9 0.4% 3.3% 5.0%
LTS10 0.2% 2.5% 3.1% 3.4% 5.5%
LTS12 0.2% 0.1% 3.1% 1.1%
LTS17 0.9% 0.7% 2.6%
LTS20 0.1% 1.9% 3.4% 2.4%
LTS22 1.6% 2.0% 3.4%
Table 3. Average Pairwise Genetic Diversity in env and Average Pairwise Divergence in env
(Between the Sequence from the Earliest Time Point and All Sequences Available
from Each Subsequent Time Point)
LTS
Genetic diversity in env Genetic divergence in env
number 2004 2008 2010 1990s 2004 2008 2010
LTS2 0.6% 0.9% 4.8% 6.5%
LTS5 0.1% 5.7%, 8.5%
LTS8 2.9% 3.4% 0.0% 6.3% 10.1% 10.2% 10.5%
LTS9 0.2% 7.4%, 2.1% 7.4%
LTS10 0.5% 0.1% 8.8% 10.5% 14.6%
LTS12 1.9% 0.1% 7.1% 7.7% 4.6%
LTS17 0.1% 3.7%, 9.1% 11.9%
LTS20 0.2% 2.8%, 8.1% 6.2% 5.6%
LTS22 2.0% 5.9%, 5.5% 7.5%
The two genetic divergences for LTS8, 17, 20, and 22 in the 1990s represent two different consensus sequences for that time point. The
two genetic divergences for LTS5 in 2010 represent two consensus sequences available from the 1990s, which were both used to calculate
the amount of genetic divergence by 2010.
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progressors is required to fully understand the implications
within subtype C-infected individuals.
Of the nine individuals infected with subtype C, who were
not suspected to be dual infected, clonal sequences generated
of both env and gag from four (LTS2, 5, 9, and 20) of the LTS
appeared highly homogeneous with a diversity of below
1.5% in env and 0.5% for gag. There are no data available for
diversity patterns within LTS; however, low levels of viral
diversity have previously been recorded within LTNPS.55–58
Bello et al.56 reported a mean heterogeneity in env of < 1% in
seven LTNPS who were in year 8 to 15 of infection. Braibant
et al.58 noted that viral diversity did not exceed 1% in three
LTNPS who had been HIV positive for over 8 years with
stable CD4 + cell counts. Low levels of diversity have been
suggested to be indicative of variants of lower fitness, which
in turn has been associated with nonprogression.59,60 How-
ever, the four individuals studied here who apparently harbor
viral populations of extremely limited diversity have all
shown signs of progression, i.e., low CD4 + cell counts and
placement on ART, so the low diversity detected may instead
be a result of homogenization of the viral population asso-
ciated with advanced disease.
It is also possible that the PCR and cloning approach may
have contributed to the limited viral diversity in some indi-
viduals included in this study. This methodmay be influenced
by reduced template detection in the early stages of PCR.
Currently it is impossible to tell to what extent experimental
design may have impacted the results. Single genome anal-
ysis has been cited as a more efficient method in the detection
of viral diversity.60 However, Jordan et al.61 comparing
standard PCR/cloning to single genome sequencing deter-
mined that both methods are likely to provide a similar
measure of viral population diversity within a given sample.
Clonal sequences generated for LTS5 were almost identical
in env and gag, indicating a possible lack of viral evolution
and restricted viral diversity rather than PCR bottlenecking.
Twenty identical clonal sequences were identified in an
LTNPS 9 years after infection in a study by Bello et al.56 with
a second LTNPS producing 39 almost identical clones 17
years after infection in the same study. In LTS8, the high
levels of viral diversity in env in 2008 (4%) were followed by
a sharp decline in diversity in 2010 (0.6%) with identical
clonal sequences generated. This restricted clonal diversity in
LTS8 2010 was not mirrored in gag clonal sequences
(1.2‘%), which points to a possible PCR bottlenecking in the
2010 env sample.
Higher levels of genetic diversity in env and gagwere seen
in LTS10 and 22, and in env for LTS12 and gag for LTS17.
Across these three individuals the intraindividual genetic
distance in gag ranged from 0.6% to 2.6%, and in env ranged
from 1.8% to 4%, which are also comparable to diversity
values described in the literature. Very few viral diversity
 LTS17 gag
17_1998
17_1989
17_2004
Ancestral Sequence
*
*
*
*
 LTS12 gag
12_1999
12_2004
12_2010
*
*
*
*
Ancestral Sequence
 LTS22 gag
22_1989
22_1998
22_2004
Ancestral Sequence
*
*
*
*
*
 LTS8 gag
8_1989 8_1999
8_2010
8_2004
Ancestral Sequence
*
*
*
*
 LTS10 gag
10_1989
10_1999
10_2010
10_2004
Ancestral Sequence
*
*
*
* *
*
*
a b c
d e
FIG. 2. Individual maximum likelihood trees generated from all gag sequences for individual long-term survivors (LTS);
(a) LTS17, (b) LTS12, (c) LTS22, (d) LTS8, (e) LTS10. Branches containing consensus sequences are labeled with the LTS
number followed by the year of sampling.  represents clones dating from 2004, and- represents clones dating from 2010.
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studies have focused on gag. Huang et al.12 described an
average of 1.7% diversity in full gag (range 0.03–3%) in
eight LTNPS 12–15 years after infection, while Braibant
et al.58 described a range of viral diversity from < 1% to 5.6%
in env V1-V5 in nine LTNPs, both similar to what was re-
corded here.
In normal progressors, as HIV-1 infection progresses, the
virus accumulates new mutations resulting in an increase in
genetic divergence over time from the original infecting
strain. This increase in divergence was also observed here in
eight of the LTS from Karonga (LTS2, 5, 8, 9, 10, 17, 20, and
22) for whom data are available. The observed increase in
divergence within these individuals indicates that evolution
and replication have not been arrested in spite of the observed
slow disease progression. Different rates of divergence were
seen between the LTS and may be the result of the different
rates of evolution of the HIV-1 virus within each individual,
making it impossible to identify a pattern unique to LTS.
Within two individuals (LTS12 and LTS20) a decrease in
viral divergence was seen after an initial increase in diver-
gence in 2004. LTS12 began ART in 2005 and LTS20 began
ART in 2006, thus altering the environment within which the
HIV-1 virus replicates and evolves. This decrease in diver-
gence, however, may also be due to the sampling of an an-
cestral lineage that had existed previously as a minor variant
and had remained latent, as has been described in other in-
dividuals. A similar pattern was shown by Bello et al.56
where 7 of 16 LTNPs were seen to show slow or arrested viral
divergence within the C2-V5 env region in conjunction with
reduced viral diversity and viral loads.
Out of the 12 LTS studied, two individuals (LTS1 and
LTS21) were identified as having possible dual infections.23
LTS1 and LTS21 are of specific interest because both of them
are still therapy free after 21 years (although LTS21 had a
CD4 count of < 200 cells/mm3 in 2010, Table 1) and both
were identified as putative dually infected individuals via
phylogenetic analyses of consensus sequences.23 Braibant
et al.58 reported that in a cohort of nine LTNPs three indi-
viduals, i.e., 30% (n= 9) were identified as being either co-
infected or superinfected with two different strains of HIV-1.
Bello et al.56 reported that one individual within a cohort of
15 LTNPs, i.e., 6.25% (n = 15) was infected with two separate
viral strains. The high level of superinfection within non-
progressors may be due to the extended period of infection,
increasing the possibility of reinfection occurring. Phyloge-
netic reconstruction of all sequences (consensus and clonal)
from each LTS and 40 control sequences, for both env and
gag, showed all sequences from each individual formed
monophyletic clusters with the exception of these two LTS
(data not shown). Further analyses (SH tests) suggests that
one of the LTS (LTS21) is likely to be dually infected, but
data from the other (LTS1) are also consistent with the
sampling of a single diverse population. Both are females; the
former individual (LTS21) was 31 in 1999 and had already
had three children from two fathers. The latter individual was
older (born circa 1950), had one husband, and had a low risk
of superinfection. Ultradeep pyrosequencing is likely to be
the best way forward for detecting multiple infections.
Studies on viral diversity of long-term survivors and
nonprogressors are often based on more regular sampling
intervals but over shorter periods of time than we have pre-
sented here. Many are focused on small subsets of patients
using different gene regions, sampling times, frequency of
sampling, and number of sequences, making it very difficult
to draw any direct comparisons or detect patterns between the
data described here and that described elsewhere. However,
this work is consistent with both types of patterns described
in the literature for diversity within LTS, i.e., some individ-
uals showing very reduced diversity, with others showing a
greater amount of diversity.55–58 The inability to differentiate
between methodological bottlenecking and detection of
highly homogeneous populations makes it difficult to draw
definitive conclusions from diversity data. Only studies em-
ploying ultradeep sequencing with the primer ID approach
will determine the extent to which both the cloning and single
genome amplification approaches have affected measures
of diversity within hosts. This study, however, suggests a
much higher proportion of CXCR4 variants within subtype
C-infected individuals than previously thought, and at an
earlier stage of infection. Additional unpublished data from
the general population in this district also suggest a higher
proportion of CXCR4-using virus than expected (Seager
et al., unpublished data). These observations may have im-
plications for treatment regimes in the future in this cohort.
Sequence Data
All sequences have been deposited into GenBank; acces-
sion numbers (KJ738309–KJ738330, KJ809622–KJ809918,
and KJ809919–KJ810193) and alignments are available from
the corresponding author.
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